COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 1782: Articles 17811-17820  | Next

SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020
Malani, A., Ramachandran, S., Tandel, V., Parasa, R., Sudharshini, S., Prakash, V., Yogananth, Y., Raju, S., Selvavinayagam, T. S.
10.1101/2021.02.03.21250949 — Posted: 2021-02-08
Emergence of SARS-CoV-2 stains harbouring the signature mutations of both A2a and A3 clade
Sarkar, R., Banerjee, D. A., Dutta, S., Chawla-Sarkar, D. M.
10.1101/2021.02.04.21251117 — Posted: 2021-02-08
COVID-19 transmission in educational institutions August to December 2020, Rhineland-Palatinate, Germany: a study of index cases and close contact cohorts
Schoeps, A., Hoffmann, D., Tamm, C., Vollmer, B., Haag, S., Kaffenberger, T., Ferguson-Beiser, K., Kohlhase-Griebel, B., Basenach, S., Missal, A., Hoefling, K., Michels, H., Schall, A., Kappes, H., Vogt, M., Jahn, K., Baernighausen, T., Zanger, P.
10.1101/2021.02.04.21250670 — Posted: 2021-02-08 Discussion: Onsite
TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
Racine-Brzostek, S. E., Karbaschi, M., Gaebler, C., Klasse, P., Yee, J., Caskey, M., Yang, H. S., Hao, Y., Chadburn, A., Shi, Y., Zuk, R., Nussenzweig, M. C., Cushing, M. M., Zhao, Z.
10.1101/2021.02.03.21251089 — Posted: 2021-02-08
Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant
Bedotto, M., Fournier, P.-E., Houhamdi, L., LEVASSEUR, A., Delerce, J., Pinault, L., Padane, A., CHAMIEH, A., TISSOT-DUPONT, H., BROUQUI, P., Sokhna, C., Azar, E., Saile, R., Mboup, S., Bitam, I., Colson, P., Raoult, D.
10.1101/2021.02.03.21250823 — Posted: 2021-02-08
SARS-CoV-2 Transmission Risk from sports Equipment (STRIKE)
Edwards, T., Kay, G. A., Aljayyoussi, G., Owen, S. I., Harland, A. R., Pierce, N. S., Calder, J. D. F., Fletcher, T., Adams, E. R.
10.1101/2021.02.04.21251127 — Posted: 2021-02-08
Self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induces protective immunity in mice
Liu, X., Song, H., Jiang, J., Gao, X., Yi, Y., Shang, Y., Li, J., Li, D., Zeng, Z., Li, Y., Zhang, Z.
10.1101/2021.02.05.428685 — Posted: 2021-02-07
Insights on SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival
Luan, B., Huynh, T.
10.1101/2021.02.06.430088 — Posted: 2021-02-07
The local topological free energy of the SARS-CoV-2 Spike protein
Baldwin, Q., Sumpter, B. G., Panagiotou, E.
10.1101/2021.02.06.430094 — Posted: 2021-02-07
Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection
Rao, Y., Wang, T.-Y., Qin, C., Espinosa, B., Liu, Q., Ekanayake, A., Zhao, J., Savas, A. C., Zhang, S., Zarinfar, M., Liu, Y., Zhu, W., Graham, N. A., Jiang, T., Zhang, C., Feng, P.
10.1101/2021.02.05.429959 — Posted: 2021-02-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).